Stocks Novartis AG

More

  • TRENTON, N.J.— Capping an enviable year, Amgen's fourth-quarter profit soared 39 percent, as the biologic drugmaker posted higher revenue for nearly all its medicines. The company's results trounced analyst expectations for the fifth-straight quarter, and Amgen boosted its 2016 financial forecast. The Thousand Oaks, California- based company said Thursday...

  • Europe ends slightly up despite poor earnings; Fed eyed Wednesday, 27 Jan 2016 | 11:30 AM ET
    Federal Reserve Chair Janet Yellen.

    European markets eked out gains Wednesday as investors tried to shake off oil's fluctuations and disappointing earnings.

  • Early movers: UTX, TUP, FCAU, ANTM, AAPL & more Wednesday, 27 Jan 2016 | 7:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Wall Street shows signs of steadying after slide Tuesday, 12 Jan 2016 | 7:11 AM ET
    Sam Zell, chairman of Equity Group Investments.

    U.S. stock futures were stronger this morning, after Wall Street seesawed Monday and closed modestly higher. But the Dow and Nasdaq remained in a correction ahead of Tuesday's trading.

  • *Zoetis, Pfizer assets could attract Bayer in future. Possible targets for the German company could include veterinary drug firm Zoetis and Pfizer's consumer health business, the two sources said. Bayer, Zoetis and Pfizer declined to comment.

  • Dec 16- Array BioPharma Inc said its experimental drug helped patients with a form of skin cancer live longer without their cancer progressing, in an ongoing late-stage study. Array is the first, and likely the only company developing an agent specifically to target this difficult-to-treat population- at least for the foreseeable future, Chief Executive Ron...

  • *Sanofi in talks to acquire Boehringer consumer health. *Boehringer to buy Sanofi's animal health arm Merial. PARIS/ LONDON, Dec 15- Sanofi and Boehringer Ingelheim are in exclusive talks over a $20 billion swap of the French pharmaceuticals company's animal health business for the family-owned German group's consumer health operation.

  • Unlocking my genome: Was it worth it? Thursday, 10 Dec 2015 | 6:50 AM ET
    DNA human genome

    Before testing your own genome, it helps to realize it can raise more questions than it answers.

  • CHICAGO, Dec 7- Alphabet Inc's life sciences unit, which was previously a part of the tech company's Google X research and development unit, has picked Verily as its new name as it seeks more visibility in the fast-growing medical technology sector. The name change follows Google's transition to the parent name Alphabet, which in October became the publicly...

  • LONDON, Dec 7- European shares rose on Monday to climb back up from three-week lows reached last week, although Electrolux slumped after its deal to buy General Electric's appliance business fell through. The broader European stock markets were supported by a rise in major healthcare stocks, with Novartis advancing on positive results for a...

  • Europe closes mixed; ECB in focus, Arcelormittal down 9% Wednesday, 2 Dec 2015 | 11:50 AM ET

    European equities closed the session mixed Wednesday as investors digested inflation numbers and contemplated the possibility of further stimulus.

  • Nov 23- Pfizer Inc's looming deal to buy Botox maker Allergan Plc for more than $150 billion will cap a record-breaking run for mergers and acquisitions in the healthcare sector, taking the cumulative value of deals in 2015 to more than $600 billion. Pfizer's tax-driven takeover of Allergan, which people familiar with the matter said won board approval on...

  • Nov 23- Pfizer Inc's looming deal to buy Botox maker Allergan Plc for more than $150 billion will cap a record-breaking run for mergers and acquisitions in the healthcare sector, taking the cumulative value of deals in 2015 to more than $600 billion. Pfizer's tax-driven takeover of Allergan, which people familiar with the matter said won board approval on...

  • Nov 20- Novartis AG said on Friday it received the U.S. Food and Drug Administration's regular approval for a drug combination to treat an aggressive form of skin cancer. The FDA approved Tafinlar and Mekinist for treatment of metastatic melanoma based on two years overall survival in patients, the company said. Tafinlar and Mekinist are among cancer drugs...

  • The settlement between a U.S. unit of Swiss drugmaker Novartis AG, the federal government and more than 40 states concerns payments that the drug manufacturer paid between 2007 and 2012 to certain specialty pharmacies to entice them to recommend prescriptions to Medicaid and Medicare patients. In the settlement, Novartis admitted to a series of facts...

  • LONDON, Nov 20- Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. The U.S. Food and Drug Administration has so far approved 38 novel drugs in 2015, more than the 34 that had been cleared by this stage a year ago and just...

  • LONDON, Nov 20- Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. The U.S. Food and Drug Administration has so far approved 37 novel drugs in 2015, more than the 34 that had been cleared by this stage a year ago and just...

  • Power Play: Companies that are connecting with consumers Wednesday, 18 Nov 2015 | 1:33 PM ET
    Novartis headquarters building in Basil, Switzerland.

    Which companies are hot with consumers?

  • LONDON, Nov 18- Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel. Biosimilar copies of expensive biotech drugs are gaining momentum in Europe, which has been faster to adopt their...

  • LONDON, Nov 18- Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel. Biosimilar copies of expensive biotech drugs are gaining momentum in Europe, which has been faster to adopt their...